A robust luminescent assay for screening alkyladenine DNA glycosylase inhibitors to overcome DNA repair and temozolomide drug resistance
Temozolomide (TMZ) is an anticancer agent used to treat glioblastoma, typically following radiation therapy and/or surgical resection. However, despite its effectiveness, at least 50% of patients do not respond to TMZ, which is associated with repair and/or tolerance of TMZ-induced DNA lesions. Stud...
Main Authors: | Ying-Qi Song, Guo-Dong Li, Dou Niu, Feng Chen, Shaozhen Jing, Vincent Kam Wai Wong, Wanhe Wang, Chung-Hang Leung |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-05-01
|
Series: | Journal of Pharmaceutical Analysis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177923000710 |
Similar Items
-
Molecular characterization of Plasmodium falciparum DNA-3-methyladenine glycosylase
by: Nattapon Pinthong, et al.
Published: (2020-08-01) -
Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways
by: Paola Matarrese, et al.
Published: (2024-07-01) -
Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
by: Chun Wang, et al.
Published: (2023-05-01) -
Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01) -
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
by: Xinyu Han, et al.
Published: (2023-10-01)